Navigation Links
Psylin Neurosciences Commences Development of Compound for Depression
Date:4/20/2009

SAN DIEGO, April 20 /PRNewswire/ -- Psylin Neurosciences Inc., a joint venture biotechnology company spun out of Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today that it has initiated IND-enabling development of a novel compound, PSN0041, for the treatment of depression.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/LA01157LOGO )

PSN0041, a peptide from Amylin's proprietary polypeptide hormone library, PHORMOL, was identified as having utility in depression after screening it in PsychoGenics' proprietary, drug discovery technologies. Not only has PSN0041 shown effects in multiple preclinical tests of depression, but also in preclinical tests of anxiety. The peptide has several anticipated advantages over current antidepressant medications including cognitive enhancement, weight loss, a lack of sexual side effects, and an enhanced safety and side effect profile. Psylin's primary aim is to advance PSN0041 rapidly through early clinical development.

"The selection of PSN0041 as a clinical candidate for depression is an important milestone for Psylin. We believe that PSN0041 validates the utility of peptides in this therapeutic arena," said Mark Gergen, Co-CEO of Psylin and Senior Vice President, Corporate Development at Amylin. "It also supports Amylin's belief that value can be derived from PHORMOL in areas outside of Amylin's core focus on diabetes and obesity therapies."

"PsychoGenics and Amylin formed Psylin in 2007 and in just two years identified PSN0041. The productivity of the partnership is the direct result of the good working relationship between both companies, the quality of Amylin's PHORMOL library, and the predictive power of PsychoGenics' proprietary, high throughput,
'/>"/>

SOURCE Psylin Neurosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
2. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
5. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
6. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
7. Amarin Signs Agreement to Acquire Ester Neurosciences
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... Aug. 20, 2014 /PRNewswire-iReach/ -- A case study ... between the school,s bioengineering department and the Intel® ... Intel® Software Academic Program, UCSD,s research focuses on ... human body.  Photo - ... the work of Dr. Todd P. Coleman ...
(Date:8/20/2014)... health of your heart, researchers have discovered. , A ... TENS machine like those designed to relieve labour pains ... raised flap at the front of the ear immediately ... changed the influence of the nervous system on the ... failing hearts too hard. , Professor Jim Deuchars, Professor ...
(Date:8/20/2014)... Cranford, NJ (PRWEB) August 20, 2014 ... solutions, announced today that it has expanded its myPROpad™ ... of the EQ-5D-5L, one of the most widely ... for measuring general health status. The EQ-5D is used ... to generate a measure that can be used to ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2'Tickling' your ear could be good for your heart 2EQ-5D™ Assessment Now Available for iPad 2
(Date:8/19/2014)... From this week,s Eos: Long-Term Ecological Research and Network-Level ... track how a wide range of ecosystems was responding ... would be particularly powerful if it coupled multiple decades ... large-scale, long-term experiments and models from dozens of different ... It is the Long-Term Ecological Research (LTER) Network, which ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... CAMBRIDGE, MA -- MIT chemical engineers have devised a ... that are released slowly over a few weeks. When ... induces the body to rapidly form new bone that ... This type of coated scaffold could offer a dramatic ... which involves transplanting bone from another part of the ...
Breaking Biology News(10 mins):This week from AGU: Long-term ecological research, predicting cholera outbreaks 2New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3
... A new study published this week in the journal ... mixing of cold, deep waters from below can change sea ... occurs in a huge region of the ocean that takes ... climate patterns, particularly global warming. Using a new measurement ...
... cell found in the trillions in our brain have made ... injury and disease such as stroke. A University of Bristol ... how astrocyte cells respond to neurological trauma. The star-shaped ... glial cell that comprise one of two main categories of ...
... research team from the School of Basic Medical ... Radix Achyranthis Bidentatae can inhibit advanced glycation end ... cortex, and improve learning and memory capabilities in ... on advanced glycation end product accumulation is associated ...
Cached Biology News:Study explains Pacific equatorial cold water region 2Study explains Pacific equatorial cold water region 3Key target responsible for triggering detrimental effects in brain trauma identified 2
Anti-human VEGFR-1/Flt-1, clone Flt-1/EWI, Monoclonal Antibody...
... adds two new Stem Cell Antibody Panels ... products. The Human Embryonic Stem Cell Marker ... antibodies against: alkaline phosphatase, Nanog, Oct-3/4, SSEA-1 ... Marker Antibody Panel Plus (Catalog # SC009) ...
Request Info...
... Platypus Contact Printing Kit contains choice of Printing Surface ... Gold over Ti adhesion layer, 1 silicon wafer coated ... or 3 plain glass slides), PDMS Stamps (3 PDMS ... squares or 100 um x 10 mm or 200 ...
Biology Products: